Interleukin-4 as a therapeutic target

Pharmacol Ther. 2023 Feb:242:108348. doi: 10.1016/j.pharmthera.2023.108348. Epub 2023 Jan 16.

Abstract

Interleukin-4 (IL-4) is a pleiotropic cytokine mainly known for its role in type 2 immunity. Therapies antagonizing or blocking IL-4 activity have been developed to counteract diseases such as atopic dermatitis and asthma. In contrast, other disorders experimentally benefit from IL-4-related effects and IL-4 recently demonstrated beneficial activity in experimental stroke, spinal cord injury and the animal model of multiple sclerosis. To exploit IL-4-related activity for therapeutic concepts, current experimental efforts include modifying the pathway without inducing type 2 immune response and targeting of the cytokine to specific tissues. Here, we review different activities of IL-4 as well as therapeutic strategies.

Keywords: Central nervous system; Interleukin-4; Neuroprotection and -repair; Translation; Type 2 inflammation.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Asthma* / drug therapy
  • Cytokines
  • Dermatitis, Atopic* / drug therapy
  • Humans
  • Interleukin-33
  • Interleukin-4 / therapeutic use

Substances

  • Cytokines
  • Interleukin-33
  • Interleukin-4
  • IL4 protein, human